1 |
Antoniou AC, Cunningham AP, Peto J, et al (2008). The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer, 98, 1457-66.
DOI
|
2 |
Bagnardi V, Rota M, Botteri E, et al (2013). Light alcohol drinking and cancer: a meta-analysis. Ann Oncol, 24, 301-8.
DOI
|
3 |
Banerji S, Cibulskis K, Rangel-Escareno C, et al (2012). Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 486, 405-9.
DOI
|
4 |
Baum M, Budzar AU, Cuzick J, et al (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359, 2131-9.
DOI
|
5 |
Bertone-Johnson ER, Chen WY, Holick MF, et al (2005). Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev, 14, 1991-7.
DOI
|
6 |
Berx G, Staes K, van Hengel J, et al (1995). Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics, 26, 281-9.
DOI
|
7 |
Boyd NF, Guo H, Martin LJ, et al (2007). Mammographic density and the risk and detection of breast cancer. N Engl J Med, 356, 227-36.
DOI
|
8 |
Bubien V, Bonnet F, Brouste V, et al (2013). High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet, 50, 255-63.
DOI
|
9 |
Cauley JA, Norton L, Lippman ME, et al (2001). Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat, 65, 125-34.
DOI
|
10 |
Chiu SY, Duffy S, Yen AM, et al (2010). Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol Biomarkers Prev, 19, 1219-28.
DOI
|
11 |
Chlebowski RT, Anderson GL, Gass M, et al (2010). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA, 304, 1684-92.
DOI
|
12 |
Claus EB, Risch N, Thompson WD (1994). Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer, 73, 643-51.
DOI
|
13 |
Collaborative Group on Hormonal Factors in Breast Cancer (2002). Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet, 360, 187-95.
DOI
|
14 |
De Felice F, Marchetti C, Musella A, et al (2015). Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Ann Surg Oncol, 22, 2876-80.
DOI
|
15 |
Cuzick J, Sestak I, Bonanni B, et al (2013). Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet, 381, 1827-34.
DOI
|
16 |
Cuzick J, Sestak I, Cawthorn S, et al (2015). Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol, 16, 67-75.
DOI
|
17 |
Cuzick J, Sestak I, Forbes JF, et al (2014). Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, 383, 1041-8.
DOI
|
18 |
DeSantis CE, Fedewa SA, Goding Sauer A, et al (2015). Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin.
|
19 |
Donnelly LS, Evans DG, Wiseman J, et al (2014). Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer, 110, 1681-7.
DOI
|
20 |
Eliassen AH, Colditz GA, Rosner B, et al (2006). Adult weight change and risk of postmenopausal breast cancer. JAMA, 296, 193-201.
DOI
|
21 |
Ellis MJ, Ding L, Shen D, et al (2012). Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 486, 353-60.
DOI
|
22 |
Emaus MJ, van Gils CH, Bakker MF, et al (2014). Weight change in middle adulthood and breast cancer risk in the EPIC-PANACEA study. Int J Cancer, 135, 2887-99.
DOI
|
23 |
Ghosh K, Vachon CM, Pankratz VS, et al (2010). Independent association of lobular involution and mammographic breast density with breast cancer risk. J Natl Cancer Inst, 102, 1716-23.
DOI
|
24 |
Fisher B, Costantino JP, Wickerham DL, et al (2005). Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst, 97, 1652-62.
DOI
|
25 |
Fisher B, Costantino JP, Wickerham DL, et al (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst, 90, 1371-88.
DOI
|
26 |
Gail MH, Costantino JP (2001). Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst, 93, 334-5.
DOI
|
27 |
Goss PE, Ingle JN, Ales-Martinez JE, et al (2011). Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med, 364, 2381-91.
DOI
|
28 |
Grady D, Cauley JA, Geiger MJ, et al (2008). Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst, 100, 854-61.
DOI
|
29 |
Hamm RM, Lawler F, Scheid D (1999). Prophylactic mastectomy in women with a high risk of breast cancer. N Engl J Med, 340, 1837-8.
|
30 |
Hartmann LC, Radisky DC, Frost MH, et al (2014). Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res, 7, 211-7.
DOI
|
31 |
Hartmann LC, Sellers TA, Schaid DJ, et al (2001). Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst, 93, 1633-7.
DOI
|
32 |
Kuerer HM, Buzdar AU, Mittendorf EA, et al (2011). Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer, 117, 39-47.
DOI
|
33 |
Howard RA, Leitzmann MF, Linet MS, et al (2009). Physical activity and breast cancer risk among pre- and postmenopausal women in the U.S. Radiologic Technologists cohort. Cancer Causes Control, 20, 323-33.
DOI
|
34 |
King MC, Marks JH, Mandell JB (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302, 643-6.
DOI
|
35 |
Kotsopoulos J, Olopado OI, Ghadirian P, et al (2005). Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res, 7, 833-43.
DOI
|
36 |
Kurian AW, Sigal BM, Plevritis SK (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol, 28, 222-31.
DOI
|
37 |
LaCroix AZ, Chlebowski RT, Manson JE, et al (2011). Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA, 305, 1305-14.
DOI
|
38 |
LaCroix AZ, Powles T, Osborne CK, et al (2010). Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst, 102, 1706-15.
DOI
|
39 |
Lazzeroni M, Serrano D, Dunn BK, et al (2012). Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Res, 14, 214.
DOI
|
40 |
Lord SJ, Lei W, Craft P, et al (2007). A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer, 43, 1905-17.
DOI
|
41 |
McTiernan A, Martin CF, Peck JD, et al (2005). Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial. J Natl Cancer Inst, 97, 1366-76.
DOI
|
42 |
Mahoney MC, Bevers T, Linos E, et al (2008). Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin, 58, 347-71.
DOI
|
43 |
Maresso KC, Tsai KY, Brown PH, et al (2015). Molecular cancer prevention: Current status and future directions. CA Cancer J Clin, 65, 345-83.
DOI
|
44 |
Maunsell E, Goss PE, Chlebowski RT, et al (2014). Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol, 32, 1427-36.
DOI
|
45 |
Meijers-Heijboer H, van Geel B, van Putten WL, et al (2001). Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med, 345, 159-64.
DOI
|
46 |
Michels KB, Willett WC (2009). The Women's Health Initiative Randomized Controlled Dietary Modification Trial: a post-mortem. Breast Cancer Res Treat, 114, 1-6.
DOI
|
47 |
Nkondjock A, Robidoux A, Paredes Y, et al (2006). Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat, 98, 285-94.
DOI
|
48 |
Pankratz VS, Hartmann LC, Degnim AC, et al (2008). Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol, 26, 5374-9.
DOI
|
49 |
Parmigiani G, Berry D, Aguilar O (1998). Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet, 62, 145-58.
DOI
|
50 |
Pharoah PD, Day NE, Duffy S, et al (1997). Family history and the risk of breast cancer: a systematic review and metaanalysis. Int J Cancer, 71, 800-9.
DOI
|
51 |
Powles TJ, Diem SJ, Fabian CJ, et al (2012). Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat, 134, 299-306.
DOI
|
52 |
Quante AS, Whittemore AS, Shriver T, et al (2015). Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk. J Natl Cancer Inst, 107.
|
53 |
Rebbeck TR, Friebel T, Lynch HT, et al (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol, 22, 1055-62.
DOI
|
54 |
Rebbeck TR, Kauff ND, Domchek SM (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst, 101, 80-7.
DOI
|
55 |
Saslow D, Boetes C, Burke W, et al (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin, 57, 75-89.
DOI
|
56 |
Shah SP, Roth A, Goya R, et al (2012). The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 486, 395-9.
DOI
|
57 |
Stephens PJ, Tarpey PS, Davies H, et al (2012). The landscape of cancer genes and mutational processes in breast cancer. Nature, 486, 400-4.
DOI
|
58 |
Tehard B, Friedenreich CM, Oppert JM, et al (2006). Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev, 15, 57-64.
DOI
|
59 |
Travis LB, Hill D, Dores GM, et al (2005). Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst, 97, 1428-37.
DOI
|
60 |
Tice JA, Miglioretti DL, Li CS, et al (2015). Breast density and benign breast disease: risk assessment to identify women at high risk of breast cancer. J Clin Oncol, 33, 3137-43.
DOI
|
61 |
Tyrer J, Duffy SW, Cuzick J (2004). A breast cancer prediction model incorporating familial and personal risk factors. Stat Med, 23, 1111-30.
DOI
|
62 |
van Lier MG, Wagner A, Mathus-Vliegen EM, et al (2010). High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol, 105, 1258-65.
DOI
|
63 |
Visvanathan K, Hurley P, Bantug E, et al (2013). Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 31, 2942-62.
DOI
|
64 |
Vogel VG, Costantino JP, Wickerham DL, et al (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 295, 2727-41.
DOI
|
65 |
Vogel VG, Costantino JP, Wickerham DL, et al (2010). Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res, 3, 696-706.
DOI
|
66 |
Vogel VG, Qu Y, Wong M, et al (2009). Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration. Clin Breast Cancer, 9, 45-50.
DOI
|
67 |
Zhang Y, Zhang M, Yuan X, et al (2015). Association between ESR1 PvuII, XbaI, and P325P polymorphisms and breast cancer susceptibility: a meta-analysis. Med Sci Monit, 21, 2986-96.
DOI
|
68 |
Wong CS, Lim GH, Gao F, et al (2011). Mammographic density and its interaction with other breast cancer risk factors in an Asian population. Br J Cancer, 104, 871-4.
DOI
|
69 |
Yang XR, Chang-Claude J, Goode EL, et al (2011). Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst, 103, 250-63.
DOI
|